Liver

Carina Biotech to Present Three Poster Presentations at AACR Annual Meeting 2024

Retrieved on: 
Monday, March 18, 2024
Ovarian cancer, Brain, Immunotherapy, Colorectal cancer, Patient, Lead, Research, Doctor of Philosophy, University of Adelaide, University, GMP, AACR, Biomedical sciences, Stomach, Liver, Pharmaceutical industry

ADELAIDE, Australia, March 18, 2024 (GLOBE NEWSWIRE) -- Carina Biotech Limited (Carina), a clinical stage cell therapy immuno-oncology company, today announced three poster presentations from studies of its LGR5-targeting CAR-T program in colorectal cancer and ovarian cancer at the American Association for Cancer Research (AACR) Annual Meeting 2024 that will take place in San Diego, California, on April 5-10.

Key Points: 
  • ADELAIDE, Australia, March 18, 2024 (GLOBE NEWSWIRE) -- Carina Biotech Limited (Carina), a clinical stage cell therapy immuno-oncology company, today announced three poster presentations from studies of its LGR5-targeting CAR-T program in colorectal cancer and ovarian cancer at the American Association for Cancer Research (AACR) Annual Meeting 2024 that will take place in San Diego, California, on April 5-10.
  • “We are looking forward to sharing data related to our LRG-5 targeted CAR-T program in three poster presentations at the upcoming AACR annual meeting.
  • One of the posters will highlight the GMP manufacturing and testing findings for our lead LGR5-targeted CAR-T cell therapy candidate CNA3103, that is currently being evaluated in a Phase 1/2 clinical trial for the treatment of adult patients with metastatic colorectal cancer,” stated Deborah Rathjen, PhD, Carina’s Chief Executive Officer.
  • “Our research team will also be presenting preclinical data that demonstrate the potential to develop our LGR5-targeting CAR-T cells as a novel immunotherapy for ovarian cancer and that expand the preclinical body of evidence across a diverse range of cancer families, including ovarian, brain, liver, and stomach, where LGR5-targeting CAR-T cells may be harnessed.”
    Lead Author: Jade Foeng, PhD, Chemokine Biology Laboratory, Department of Molecular and Biomedical Science, The University of Adelaide, South Australia

Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with SARS-CoV-2

Retrieved on: 
Monday, March 18, 2024
CCL7, COVID, Major, BMJ Open, IL-6, AKI, Inflammation, Lung, Biomarker, Hospital, Acute respiratory distress syndrome, TMX Group, CXCL10, Acute kidney injury, SARS-CoV-2, Human, TSX, Chemokine, Arch, Cytokine, Periodic breathing, Phase, OTCQB, CXCL8, Liver, Somayaji, BMJ, Randomness, Pharmaceutical industry

New biomarker data from the pandemic Phase II trial, provides further scientific rationale for Arch to bring LSALT peptide into larger trials to inhibit DPEP-1 mediated organ inflammation.

Key Points: 
  • New biomarker data from the pandemic Phase II trial, provides further scientific rationale for Arch to bring LSALT peptide into larger trials to inhibit DPEP-1 mediated organ inflammation.
  • Arch is currently performing a Phase II human trial to support LSALT peptide as a first ever treatment for preventing cardiac surgery-associated acute kidney injury.
  • The results of the Phase II trial provided first-ever evidence validating DPEP-1 as a mediator of organ inflammation and therapeutic target in humans.
  • The new data provides more scientific rationale for Arch to advance LSALT peptide to prevent leukocyte recruitment and organ inflammation for other indications, including a larger Phase II trial targeting cardiac surgery-associated AKI, which recently began recruiting patients.

Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand

Retrieved on: 
Monday, March 18, 2024
Civil service commission, Neuroblastoma, Ototoxicity, Partnership, Central nervous system, ANZ, Risk, FENC, Patient, Hepatoblastoma, Neoplasm, Cancer, MHRA, TSX, Hearing loss, European, Cisplatin, Safety, European Commission, Liver, Arnold & Porter, Pharmaceutical industry

RESEARCH TRIANGLE PARK, N.C. and UXBRIDGE, United Kingdom, March 17, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, and Norgine, a leading European specialist pharmaceutical company, today announced an exclusive licensing agreement under which Norgine will commercialize PEDMARQSI® in Europe, Australia and New Zealand. PEDMARQSI is the first and only approved therapy in the EU and U.K. for the prevention of ototoxicity (hearing loss) induced by cisplatin chemotherapy in patients 1 month to

Key Points: 
  • Norgine will be responsible for all commercialization activities in the licensed territories and will hold all marketing authorizations in the licensed territories.
  • It is estimated that more than 5,000 pediatric patients annually are eligible for platinum-based chemotherapy in Europe.
  • PEDMARQSI was granted EU marketing authorization by the European Commission in June 2023, and received UK approval from the MHRA in October 2023.
  • The studies compared PEDMARQSI plus cisplatin-based regimens to cisplatin-based regimens alone for the reduction of cisplatin-induced hearing loss in pediatric patients.

Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects

Retrieved on: 
Monday, March 18, 2024
Proton, Magnetic resonance imaging, Patient, Biomarker, MASH, Trial of the century, MBA, Doctor of Philosophy, Principal investigator, Therapy, Safety, Pharmacokinetics, Liver, Magnetic resonance, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced the initiation of the Phase 2a HERALD study of ALG-055009 in subjects with metabolic dysfunction-associated steatohepatitis (MASH). Screening of subjects has begun at clinical study sites across the U.S.

Key Points: 
  • The Phase 2a study is being led by Principal Investigator, Dr. Stephen Harrison
    SOUTH SAN FRANCISCO, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced the initiation of the Phase 2a HERALD study of ALG-055009 in subjects with metabolic dysfunction-associated steatohepatitis (MASH).
  • Screening of subjects has begun at clinical study sites across the U.S.
    “ALG-055009 has enhanced potency, greater beta selectivity, and a favorable PK profile.
  • We believe that these optimized pharmacologic properties may result in improved therapeutic outcomes for patients living with MASH.
  • The initiation of the HERALD study is an important next step in achieving our goal to create a best-in-class thyroid hormone receptor beta agonist,” stated Lawrence Blatt, Ph.D., MBA, Chairman, President, and CEO of Aligos Therapeutics.

University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Retrieved on: 
Friday, March 15, 2024
Libin Cardiovascular Institute, Kidney, User experience, Assistant, AKI, Patient, Kidney disease, Inflammation, Hospital, TMX Group, Acute kidney injury, University, Ischemia, Injury, Dispute board, IRI, Science Advances, Arch, Oxygen, Reperfusion, Placebo-controlled study, Division, Phase, OTCQB, Liver, Yolo Bypass, Randomness, Pharmaceutical industry

LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.

Key Points: 
  • LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.
  • “We know that acute kidney injury impairs recovery and can negatively affect long-term outcomes following heart surgery.
  • The CS-AKI Phase II trial is an international multi-center, randomized, double-blind, placebo-controlled study of LSALT peptide.
  • Details of the Phase II trial, entitled “ Phase 2 Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of LSALT peptide for the Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery” can be viewed at clinicaltrials.gov .

HepaRegeniX publishes data for its first-in-class MKK4 inhibitor HRX-215 for the treatment of acute and chronic liver diseases in Cell

Retrieved on: 
Thursday, March 14, 2024
Liver, Liver failure, DOI, Cell death, Regeneration, Clinical professor, Colorectal cancer, Transplant, Gesellschaft mit beschränkter Haftung, Hepatectomy, Risk, Patient, MKK4, Mayo Clinic, Manuscript, Liver transplantation, Teaching hospital, Human, MAP, Liver regeneration, Hepatocyte, PHLF, Regenerative medicine, Safety, Hepatology, Liver disease, Dietary supplement

HRX-215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).

Key Points: 
  • HRX-215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).
  • “The positive results in terms of safety and tolerability confirm our intention to soon offer a drug that has the potential to revolutionize the treatment of severe liver diseases.
  • The data pave the way for further Phase II studies evaluating the efficacy of HRX-215 in humans,” emphasizes Dr. Wolfgang Albrecht, COO of HepaRegeniX.
  • Further, HRX-215 was also able to protect hepatocytes from cell death in a model for acute liver injury.

GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell Modulators

Retrieved on: 
Thursday, March 14, 2024
Retinoic acid, Patient, CIPO, Doctor of Philosophy, Idiopathic pulmonary fibrosis, GRI, IPF, RAR, Treatment, Oxygen, Patent, Interim, NKT, Idiopathic disease, Liver, Movement, Natural killer T cell, Pharmaceutical industry

LA JOLLA, CA, March 14, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that the Canadian Intellectual Property Office (CIPO) has issued a notice of allowance for Patent Application No. 3,007,970 titled, "Prevention and Treatment of Inflammatory Conditions." A patent from the recently allowed application is expected to be issued in the coming months.

Key Points: 
  • A patent from the recently allowed application is expected to be issued in the coming months.
  • “We have remained committed to bolstering our intellectual property protection across our innovative pipeline of NKT cell modulators.
  • IPF is a rare chronic progressive pulmonary disease with abnormal scarring of the lung blocking the movement of oxygen into the bloodstream.
  • For more information about the Company’s innovative pipeline of NKT cell regulators for the treatment of inflammatory, fibrotic and autoimmune diseases, visit gribio.com .

High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization

Retrieved on: 
Wednesday, March 13, 2024
Lung cancer, Pollination, Bee, Metabolism, Culture, Gene, Algorithm, National Medal, Brain, Growth, Aditi, Gene expression, Survival, Cell, Bone marrow, Trustee, School, Research, Science News, RET, Highlands Ranch, Colorado, Death, Macrophage, ARD International Music Competition, Society, Student, Thought, Nobel Prize, STEM, CO, Cancer, MYC, ChatGPT, Machine learning, Society for Science, Liver, STS, Pharmaceutical industry

The 2024 finalists demonstrated extensive scientific knowledge through research and interviews while showcasing their commitment to addressing societal issues, passion for discovery, noteworthy leadership and community involvement.

Key Points: 
  • The 2024 finalists demonstrated extensive scientific knowledge through research and interviews while showcasing their commitment to addressing societal issues, passion for discovery, noteworthy leadership and community involvement.
  • This knowledge sheds light on what these algorithms are “thinking,” which can help make them more effective, fair and safe.
  • “Congratulations to the winners of this year’s Regeneron Science Talent Search,” said Maya Ajmera, President and CEO, Society for Science and Executive Publisher, Science News.
  • In total, Regeneron awarded $3.1 million in prizes through the Regeneron Science Talent Search 2024, including $2,000 to each of the top 300 scholars and their schools.

ProQR Announces Year End 2023 Operating and Financial Results

Retrieved on: 
Wednesday, March 13, 2024
Trident, Eli Lilly, Exercise, ProQR, Patient, IP, Therapy, Lilly, RNA editing, Cholestasis, Rett syndrome, Research, Cardiovascular disease, Partnership, Pseudouridine, NTCP, RNA, Functional, Uridine, MECP2, Oligonucleotide, ACTB, LPL, Annual report, Conference, Patent, Biomarker, Mouse, RSRT, Eli Lilly and Company, Liver, ANGPTL3

(Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today reported its financial and operating results for the year ended December 31, 2023, and provided a business update.

Key Points: 
  • (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today reported its financial and operating results for the year ended December 31, 2023, and provided a business update.
  • At December 31, 2023, ProQR held cash and cash equivalents of €118.9 million, compared to €94.8 million at December 31, 2022.
  • The Company experienced a net positive cash flow from operating activities in 2023 primarily due to the receipt of the Lilly up-front payment of $60 million in February 2023.
  • For further financial information for the period ended December 31, 2023, please refer to our 2023 Annual Report on Form 20-F and our Statutory Annual Report which will be available on our website, www.

Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types

Retrieved on: 
Tuesday, March 12, 2024
HCC, Plasma, Head, Dicarboxylic acid, Immunotherapy, Patient, Standard of care, Cancer, Society, Bevacizumab, Pancreatic cancer, Therapy, SITC, FFA, Liver, Tempest, Medical imaging

BRISBANE, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced a poster presentation at the Society for Immunotherapy of Cancer (SITC) 2024 Spring Scientific Meeting highlighting preclinical data showing potent anti-tumor activity in several cancer models treated with TPST-1120 alone or with immune checkpoint inhibitors.

Key Points: 
  • BRISBANE, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced a poster presentation at the Society for Immunotherapy of Cancer (SITC) 2024 Spring Scientific Meeting highlighting preclinical data showing potent anti-tumor activity in several cancer models treated with TPST-1120 alone or with immune checkpoint inhibitors.
  • “Data presented at the SITC Spring Scientific Meeting bolster our mechanistic understanding of PPARα blockade in cancer patients and reinforce a basis for the ongoing late-stage clinical development of TPST-1120,” said Sam Whiting, M.D., Ph.D., chief medical officer and head of R&D at Tempest.
  • Clinical response and biomarker findings support that inhibition of PPARα may be an effective therapeutic strategy for the treatment of cancer.
  • These findings complement positive data reported in October 2023 from a global randomized phase 1b/2 study of TPST-1120 in combination with atezolizumab and bevacizumab in first-line patients with advanced HCC.